Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B
This study suggests that Hecolin is safe and immunogenic in patients with CHB with compensated liver cirrhosis, supporting its use in preventing HEV superinfection in this high-risk population.
Authors
- Xuejiao Liao
- Liping Zhang (ORCID: https://orcid.org/0000-0001-7580-0916)
- Xinwu Wang (ORCID: https://orcid.org/0000-0003-0172-9971)
- Shuting Wu (ORCID: https://orcid.org/0000-0002-8635-1834)
- Changxiang Lai
- Jingke Dong
- Zhenghua Ma
- Yingying Su (ORCID: https://orcid.org/0000-0002-4532-512X)
- Fang Wang (ORCID: https://orcid.org/0000-0002-7031-3788)
- Haiyan Wang (ORCID: https://orcid.org/0000-0001-7918-6765)
- Zhiyu Li (ORCID: https://orcid.org/0000-0001-6492-9511)
- Dapeng Li (ORCID: https://orcid.org/0000-0002-1816-3217)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-6601-9180)
- Zheng Zhang (ORCID: https://orcid.org/0000-0002-3544-1389)
- Yanling Chen (ORCID: https://orcid.org/0000-0003-1603-9121)
- Qing He (ORCID: https://orcid.org/0000-0003-2873-1297)
- Xiaobin Wan
- Qiyuan Tang
Institutions
- Xiamen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Southern University of Science and Technology (CN)
- Shenzhen Third People’s Hospital (CN)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1016/j.cmi.2025.02.027
- Citations
- 3
- Primary Topic
- Hepatitis Viruses Studies and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 3.97